Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

(2022) Alissa J. Cooper et al.   Nature Reviews Clinical Oncology

Loss of MIG-6 results in endometrial progesterone resistance via ERBB2

(2022) Jung-Yoon Yoo et al.   Nature Communications

EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma

(2022) Qibiao Wu et al.   Cancer Discovery

Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4/6

(2022) Alexey V. Sorokin et al.   CANCER RESEARCH

KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy

(2022) Meagan B. Ryan et al.   Cell Reports

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

(2022) Jill Hallin et al.   NATURE MEDICINE

The current state of the art and future trends in RAS-targeted cancer therapies

(2022) Salman R. Punekar et al.   Nature Reviews Clinical Oncology

Combining neratinib with CDK4/6, mTOR and MEK inhibitors in models of HER2-positive cancer

(2021) Ming Zhao et al.   CLINICAL CANCER RESEARCH

BCL6 confers KRAS-mutant non–small-cell lung cancer resistance to BET inhibitors

(2021) Jiawei Guo et al.   JOURNAL OF CLINICAL INVESTIGATION

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Precision oncology in metastatic colorectal cancer — from biology to medicine

(2021) Federica Di Nicolantonio et al.   Nature Reviews Clinical Oncology

The origins and genetic interactions of KRAS mutations are allele- and tissue-specific

(2021) Joshua H. Cook et al.   Nature Communications

A Review of the Diagnosis and Treatment of Metastatic Colorectal Cancer

(2021) Jeffrey Bien et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

EGFR activation limits the response of liver cancer to lenvatinib

(2021) Haojie Jin et al.   NATURE

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

(2021) Ferdinandos Skoulidis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired Resistance to KRASG12C Inhibition in Cancer

(2021) Mark M. Awad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apoptosis-inducing activity of synthetic hydrocarbon-stapled peptides in H358 cancer cells expressing KRASG12C

(2021) Cuicui Li et al.   Acta Pharmaceutica Sinica B

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor

(2021) Xiaolun Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

(2021) Marwan G Fakih et al.   LANCET ONCOLOGY

Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives

(2020) E. Martinelli et al.   ANNALS OF ONCOLOGY

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition

(2020) Jenny Y. Xue et al.   NATURE

Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer

(2020) Emilie Picard et al.   Frontiers in Immunology

The Frequency of Ras Mutations in Cancer

(2020) Ian A. Prior et al.   CANCER RESEARCH

EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer

(2020) Vito Amodio et al.   Cancer Discovery

Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling

(2020) Huai-Xiang Hao et al.   CLINICAL CANCER RESEARCH

Therapeutics Targeting Mutant KRAS

(2020) Kyaw Z. Thein et al.   Annual Review of Medicine

Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy

(2019) Davide Ciardiello et al.   CANCER TREATMENT REVIEWS

Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies

(2019) NaNa Keum et al.   Nature Reviews Gastroenterology & Hepatology

Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer

(2019) Ye Yao et al.   Cell Stem Cell

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer

(2018) Rona Yaeger et al.   CANCER CELL

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer

(2018) Ryan B. Corcoran et al.   Cancer Discovery

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

(2018) Sandra Misale et al.   CLINICAL CANCER RESEARCH

OncogenicKrasdrives invasion and maintains metastases in colorectal cancer

(2017) Adam T. Boutin et al.   GENES & DEVELOPMENT

The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion

(2017) Runqiu Jiang et al.   Nature Communications

Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells

(2017) Chun Xie et al.   Frontiers in Pharmacology

The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations

(2016) H Endo et al.   ONCOGENE

Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes

(2015) J. F. Linnekamp et al.   CANCER RESEARCH

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

(2015) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma

(2015) T. K. Maity et al.   Cancer Discovery

Colorectal cancer

(2015) Ernst J. Kuipers et al.   Nature Reviews Disease Primers

Wentilactone B induces G2/M phase arrest and apoptosis via the Ras/Raf/MAPK signaling pathway in human hepatoma SMMC-7721 cells

(2013) Z Zhang et al.   Cell Death & Disease

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling

(2012) Amy Young et al.   Cancer Discovery

A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation

(2010) Yuri Frosi et al.   JOURNAL OF CELL BIOLOGY

Negative Regulation of the EGFR-MAPK Cascade by Actin-MAL-Mediated Mig6/Errfi-1 Induction

(2009) Arnaud Descot et al.   MOLECULAR CELL